Synergistic Botanical Formulation for HSV-1 Resistance Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current OTC and pharmaceutical treatments for herpes simplex virus type 1 (HSV1) infections, commonly known as cold sores, have limited efficacy and can lead to viral resistance, while botanical formulations often lack synergistic value due to similar mechanisms of action and inconsistent activity based on marker compounds.
Innovation Solution
Develop synergistic botanical formulations by identifying botanical extracts with different mechanisms of action (extracellular and intracellular) and hydrophobic/hydrophilic properties, standardized through in vitro assays for antiviral activity, combining them to enhance antiviral potency and prevent resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current OTC or pharmaceutical topical treatments are used for cold sores, then the treatment provides some antiviral effect, but the efficacy is limited and viral resistance can develop
Solution Approach 1:
The patent combines multiple botanical extracts (Melissa officinalis, Hamamelis virginiana, Prunella vulgaris, Tagetes lucida) into a single formulation where each component targets different stages of the viral replication cycle. This synergistic combination achieves greater antiviral efficacy (10-fold greater than current products) while preventing viral resistance through multi-target action.
2Ease of manufacture
If botanical formulations are created based on marker compounds, then the formulation process is simplified, but the antiviral activity becomes inconsistent due to seasonal and geographical variations
Solution Approach 1:
The patent shifts the standardization parameter from marker compound concentration to actual antiviral activity measurement. Each botanical extract is standardized based on its IC50 value determined through in vitro antiviral assays, ensuring consistent therapeutic effect regardless of seasonal or geographical variations in the source material.
3Device complexity
If botanical extracts with the same mechanism of action are combined, then the formulation is easier to develop, but no synergistic value is achieved
Solution Approach 1:
The patent segments the viral replication cycle into multiple targets (attachment, entry, replication, assembly, release) and selects botanical extracts that act at different stages. This segmentation approach identifies four extracts with distinct mechanisms: Melissa officinalis (attachment inhibition), Hamamelis virginiana (entry inhibition), Prunella vulgaris (replication inhibition), and Tagetes lucida (assembly/release inhibition), creating synergistic therapeutic value.
Data Source
AI summary
A synergistic botanical formulation and related methods for the treatment of herpes virus infections, particularly herpes simplex virus type 1 (HSV-1), are disclosed. The formulation comprises at least one botanical extract with an extracellular antiviral mechanism and at least one botanical extract with an intracellular antiviral mechanism, selected through in vitro assays to provide complementary modes of action. Extracts are prepared under conditions that selectively isolate hydrophilic or hydrophobic constituents, and are combined in proportions based on individual antiviral activity to maximize synergistic inhibition of viral replication. The formulation is standardized to measured biological activity rather than marker compounds, ensuring consistent therapeutic performance despite variability in botanical sources. When administered topically, the formulation reduces lesion healing time, increases antiviral potency compared to conventional over-the-counter treatments, and decreases the likelihood of viral resistance development. Pharmaceutical compositions, methods of preparation, and treatment protocols are also provided.